5/6, 12:11 AM (Source: TeleTrader)
more TeleTrader news


Chart for: Novavax

Novavax publishes its COVID vaccine trial results

A study of Novavax Inc.'s coronavirus vaccine published in the New England Journal of Medicine revealed additional information from the initial analysis of the jab, which was the first to demonstrate efficiency against both the UK and South Africa variants of the virus.

In Phase 2b clinical trial conducted in South Africa, data showed that prior infection with the original strain did not protect against an infection of the virus variant circulating in South Africa, however, that there may be a "modest protective effect of prior exposure."

"This data publication reinforces the encouraging safety profile and cross-protective effect across variants seen in studies of our vaccine to-date," said Novavax President of Research and Development Dr. Gregory Glenn.

Breaking the News / NL